DaVita CEO Says Government 'Will Have To Pay More' To Draw New Capital To Dialysis

Javier Rodriguez pushed back on how HHS's kidney plan portrays dialysis, citing 90% government coverage and about 1% Medicare increases.

Share
DaVita CEO Says Government 'Will Have To Pay More' To Draw New Capital To Dialysis

DaVita CEO Javier Rodriguez said on the company's Thursday third-quarter earnings call that a new federal kidney care plan misjudges dialysis and that "the government will have to pay more" if it wants new capital in the field. The company reported adjusted earnings per share of $3.82 for the quarter.

A frustrated response to the HHS plan

DaVita, which runs outpatient dialysis centers for patients whose kidneys have failed, said it shares the goals of the Kidney Care National Plan that HHS released the week before. Asked by a Barclays analyst for his first impressions, Rodriguez said he reached out to the administration right away to be "part of the solution."

The part that bothered him was the portrayal of dialysis. That was "a bit frustrating," he said, adding that the rest of the plan is something he is "totally behind."

He also pointed to positives inside the dialysis section: the plan's push to solve for innovation in the payment bundle and to reduce regulatory burden.

The 90% government-mix argument

Rodriguez said "90% of patients are covered by the government insurance with roughly 1% Medicare increase for the past decade." The plan, he argued, assumes the model can accept private insurers' cross-subsidy of that gap, which he put at one in 10 patients.

Attracting new capital, one of the plan's aims, means solving that dynamic. "One of the things is the government will have to pay more," he said.

On competition, he said DaVita welcomes more of it, but the limit comes from how hard it is to care for a vulnerable, high-need population at a 90% government mix, not from how DaVita operates. He also argued that scale and expertise are underappreciated, saying 92% of patients in rural communities are within 10 miles of its centers and that a counterweight to "big pharma and big insurance" is needed.

Charitable premium assistance under review

A Bank of America analyst asked about the plan's attention to DaVita's exposure to the American Kidney Fund, which administers charitable premium assistance grants. Rodriguez said the grants have been through investigations, inspections, rulemaking and legislative scrutiny, and that all concluded they benefit a vulnerable population and that the program follows the rules.

If the program were diluted, he said, more patients would end up paid by the government and less capital would come in, which he called ironic and contrary to the plan's intent to bring more competition. He said the numbers DaVita disclosed roughly eight years ago have stayed flat.

Policy work still ahead

Rodriguez said many elements of the plan need policy development and possibly congressional action before turning into specific steps. DaVita plans to work with HHS and other agencies as that proceeds.

Separately, he said CMS released its final dialysis payment rule the day before, with a headline rate increase of 3.5% for large dialysis organizations, up 1.5% from the proposal. DaVita narrowed its 2026 adjusted operating income outlook to a range of $2.175 billion to $2.25 billion.

DaVita's market value stood at $11.7 billion after Thursday's session.

Sources

More on DaVita

All DaVita (DVA) coverage →